ClinVar Miner

Submissions for variant NM_000441.2(SLC26A4):c.85G>C (p.Glu29Gln) (rs111033205)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000036509 SCV000060164 pathogenic Rare genetic deafness 2015-09-14 criteria provided, single submitter clinical testing The p.Glu29Gln variant in SLC26A4 has been identified in multiple individuals wi th hearing loss and temporal bone abnormalities including over 15 probands who w ere compound heterozygous with another pathogenic variant in SLC26A4, and it has segregated in three affected siblings (Albert 2006, Campbell 2001, Gardner 2006 , Ladsous 2014, Pera 2008, Pourova 2010, Rendtorff 2013, LMM unpublished data). Functional studies have demonstrated that this variant impacts the protein func tion (Pera 2008). In summary, this variant meets our criteria to be classified as pathogenic for DFNB4 nonsyndromic hearing loss or Pendred syndrome in an auto somal recessive manner.
Illumina Clinical Services Laboratory,Illumina RCV000778809 SCV000915189 pathogenic SLC26A4-Related Disorders 2018-11-24 criteria provided, single submitter clinical testing Across a selection of the available literature, the SLC26A4 c.85G>C (p.Glu29Gln) missense variant has been reported in at least nine studies in which it was identified in a total of 18 individuals, including in a compound heterozygous state in 14 individuals, in a heterozygous state in three individuals, in a double heterozygous state in one individual and in one individual with unknown zygosity. Affected individuals were diagnosed with either Pendred syndrome, an autosomal recessive form of deafness, or enlarged vestibular aqueduct or Mondini dysplasia (Campbell et al. 2001; Prasad et al. 2004; Blons et al. 2004; Alberts et al. 2006; Yang et al. 2007; Pera et al. 2008; Pourova et al. 2010; Rendtorff et al. 2013; Ladous et al. 2014). The p.Glu29Gln variant was found to segregate in at least one study (Yang et al. 2007). The variant was absent from 469 controls and is reported at a frequency of 0.000229 in the European (non-Finnish) population of the Genome Aggregation Database. Functional studies using fluorimetric measurements showed that the p.Glu29Gln variant protein has reduced chloride/iodide transport (Pera et al. 2008). Based on the collective evidence, the p.Glu29Gln variant is classified as pathogenic for SLC26A4-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Invitae RCV001040420 SCV001203995 pathogenic not provided 2020-10-01 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid with glutamine at codon 29 of the SLC26A4 protein (p.Glu29Gln). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and glutamine. This variant is present in population databases (rs111033205, ExAC 0.01%). This variant has been observed in several individuals affected with SLC26A4-related conditions (PMID: 11317356, 20597900, 16570074, 15355436, 25394566). ClinVar contains an entry for this variant (Variation ID: 4839). This variant has been reported to affect SLC26A4 protein function (PMID: 19017801). This variant disrupts the p.Glu29 amino acid residue in SLC26A4. Other variants that disrupt this residue have been observed in individuals with SLC26A4-related conditions (PMID: 22285650, 25372295), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.
CeGaT Praxis fuer Humangenetik Tuebingen RCV001040420 SCV001249281 pathogenic not provided 2019-02-01 criteria provided, single submitter clinical testing
GeneDx RCV001040420 SCV001779676 pathogenic not provided 2021-03-08 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect due to reduced iodide transport activity (Pera et al., 2008); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 31589614, 31541171, 23336812, 20597900, 16570074, 15355436, 15099345, 18285825, 16950989, 29372807, 14679580, 19017801, 11317356, 17503324, 24224479)
OMIM RCV000005111 SCV000025287 pathogenic Deafness, autosomal recessive 4, with enlarged vestibular aqueduct 2008-08-01 no assertion criteria provided literature only
Counsyl RCV000169251 SCV000220535 pathogenic Pendred syndrome 2019-06-09 no assertion criteria provided clinical testing
Lupski Lab, Baylor-Hopkins CMG, Baylor College of Medicine RCV000656195 SCV000678389 likely pathogenic Wolff-Parkinson-White pattern 2017-07-14 no assertion criteria provided research This variant was identified in an individual with Wolff-Parkinson-White syndrome
Genetic Testing Center for Deafness, Department of Otolaryngology Head & Neck Surgery,Institute of Otolaryngology, Chinese PLA General Hospital RCV000005111 SCV000902384 likely pathogenic Deafness, autosomal recessive 4, with enlarged vestibular aqueduct 2019-02-26 no assertion criteria provided case-control
Natera, Inc. RCV000169251 SCV001455791 pathogenic Pendred syndrome 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.